Abstracts tagged "Amyloidosis and ankylosing spondylitis (AS)"

Abstract Number: 523 • 2013 ACR/ARHP Annual Meeting
Association Between The Presence Of Amyloidosis In Patients With Ankylosing Spondylitis and Polymorphisms In Type 1/Type 2 Serum Amyloid A Protein Genes, Mediterranean Fever Genes
Gozde Yildirim Cetin¹, Eda Ganiyusufoglu², Dilek Solmaz³, Yonca Cagatay⁴, Sibel Yilmaz Oner⁵, Burak Erer⁶, Hasan Sabit Sagliker⁷, Ali Berkant Avci⁸, Servet Akar³, Omer Nuri Pamuk⁹, Metin Kilinc², Timucin Kasifoglu¹⁰, Haner Direskeneli⁵ and Mehmet Sayarlioglu¹¹, ¹Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, ²Sutcu Imam University, School of Medicine, Department of Biochemistry Research Laboratory, Kahramanmaras, Turkey, ³Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ⁴Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁵Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine,, Istanbul, Turkey, ⁷Sutcu Imam University, School of Medicine, Department of Internal Medicine, Kahramanmaras, Turkey, ⁸Antalya University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey, ⁹Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ¹⁰Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, ¹¹Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey
Background/Purpose: Ankylosing spondylitis (AS) is a chronic autoinflammatory disease. The most severe complication of this disease is development of renal amyloidosis. The etiology of AS remains…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].